PapersFlow Research Brief
Renal and related cancers
Research Guide
What is Renal and related cancers?
Renal and related cancers are malignancies originating in the kidney and associated structures, such as clear-cell renal-cell carcinoma and Wilms tumor, often linked to molecular pathways including telomerase activity and targeted therapies like sunitinib and sorafenib.
The field encompasses 53,601 works on molecular mechanisms in kidney-related diseases, including renal-cell carcinoma and Wilms tumor. Research covers targeted therapies, with sunitinib extending progression-free survival in metastatic renal-cell carcinoma compared to interferon alfa (Motzer et al., 2007). Sorafenib prolongs progression-free survival in advanced clear-cell renal-cell carcinoma after prior therapy failure (Escudier et al., 2007).
Topic Hierarchy
Research Sub-Topics
Kidney Organoids Nephrogenesis
Researchers generate segmental nephron-containing organoids from human PSCs to model embryonic kidney development. Studies validate organoid fidelity to in vivo nephrogenesis through single-cell transcriptomics.
WT1 Gene Renal Development
Functional studies elucidate WT1 transcription factor roles in nephron progenitor maintenance and epithelial differentiation. Research links WT1 mutations to Denys-Drash and Frasier syndromes.
GDNF Ret Signaling Kidney Morphogenesis
This area dissects GDNF/Ret-Wnt11 feedback regulating ureteric bud branching and nephron induction. Studies model congenital anomalies of kidney and urinary tract (CAKUT) using organ cultures.
Podocyte Development Molecular Mechanisms
Researchers characterize podocyte specification from renal progenitors via FoxC2, Wt1, and Podocin networks. Lineage tracing reveals podocyte turnover and regeneration potential.
Wilms Tumor Molecular Pathogenesis
Genomic studies identify recurrent WT1, CTNNB1, and 11p15 imprinting alterations driving nephroblastoma. Research develops mouse models recapitulating multi-hit tumorigenesis.
Why It Matters
Targeted therapies have improved outcomes in metastatic renal-cell carcinoma, where sunitinib achieved longer progression-free survival and higher response rates than interferon alfa in clinical trials NCT00098657 and NCT00083889 (Motzer et al., 2007). In advanced clear-cell renal-cell carcinoma, sorafenib extended progression-free survival versus placebo in trial NCT00073307, despite increased toxicity (Escudier et al., 2007). Telomerase activity associates specifically with 98 of 100 immortal human cell populations and cancer cells across 18 tissues, distinguishing them from 22 mortal populations (Kim et al., 1994). These findings support precision oncology applications in renal cancers, guiding patient selection for therapies based on tumor biology.
Reading Guide
Where to Start
"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma" by Motzer et al. (2007), as it provides clinical evidence of therapy efficacy with specific trial results on progression-free survival, accessible for understanding renal cancer treatment basics.
Key Papers Explained
Takahashi and Yamanaka (2006) "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors" established iPSC generation, enabling Yu et al. (2007) "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells" to adapt it for humans with OCT4, SOX2, NANOG, LIN28. Kim et al. (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer" links telomerase to cancer immortality, foundational for renal cancer studies. Motzer et al. (2007) "Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma" and Escudier et al. (2007) "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" build on these by applying targeted therapies to clinical renal cancer outcomes.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes molecular mechanisms in kidney organoids and genes like WT1 for modeling renal cancers. Clinical focus remains on tyrosine kinase inhibitors like sunitinib and sorafenib. No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Induction of Pluripotent Stem Cells from Mouse Embryonic and A... | 2006 | Cell | 26.1K | ✓ |
| 2 | Induced Pluripotent Stem Cell Lines Derived from Human Somatic... | 2007 | Science | 10.2K | ✕ |
| 3 | Specific Association of Human Telomerase Activity with Immorta... | 1994 | Science | 7.1K | ✕ |
| 4 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carc... | 2007 | New England Journal of... | 5.7K | ✓ |
| 5 | Viable offspring derived from fetal and adult mammalian cells | 1997 | Nature | 4.9K | ✕ |
| 6 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma | 2007 | New England Journal of... | 4.7K | ✓ |
| 7 | Analysis of nanoparticle delivery to tumours | 2016 | Nature Reviews Materials | 4.7K | ✕ |
| 8 | Generation of germline-competent induced pluripotent stem cells | 2007 | Nature | 4.2K | ✕ |
| 9 | Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) ma... | 2003 | Journal of Clinical In... | 3.9K | ✓ |
| 10 | TSC2 Mediates Cellular Energy Response to Control Cell Growth ... | 2003 | Cell | 3.8K | ✓ |
Frequently Asked Questions
What is the role of sunitinib in metastatic renal-cell carcinoma?
Sunitinib treatment resulted in longer progression-free survival and higher response rates compared to interferon alfa in patients with metastatic renal-cell carcinoma. This was demonstrated in clinical trials NCT00098657 and NCT00083889 (Motzer et al., 2007). The therapy targets vascular endothelial growth factor receptors in renal tumors.
How does sorafenib affect advanced clear-cell renal-cell carcinoma?
Sorafenib prolongs progression-free survival compared to placebo in patients with advanced clear-cell renal-cell carcinoma after previous therapy failure. The phase 3 trial was NCT00073307 (Escudier et al., 2007). Treatment increases toxic effects but offers clinical benefit.
What is the association between telomerase and renal cancers?
Human telomerase activity specifically associates with immortal cells and cancer, present in 98 of 100 immortal populations versus none of 22 mortal populations from 18 tissues (Kim et al., 1994). This supports telomerase as a marker for renal cancer proliferation. Assays detect activity enabling indefinite cell division.
What defines pluripotent stem cells in kidney research?
Induced pluripotent stem cells from human somatic cells are generated using OCT4, SOX2, NANOG, and LIN28 factors (Yu et al., 2007). Mouse versions use defined factors from fibroblasts (Takahashi and Yamanaka, 2006). These cells model kidney development and related cancers like Wilms tumor.
How many works address renal and related cancers?
The field includes 53,601 works focused on molecular biology of kidney cancers and development. Topics span renal-cell carcinoma therapies and Wilms tumor genetics. Growth data over 5 years is not available.
Open Research Questions
- ? How can telomerase inhibitors improve outcomes in telomerase-positive renal cancers?
- ? What combinations of sunitinib and sorafenib optimize progression-free survival in advanced renal-cell carcinoma?
- ? Which molecular pathways link TSC2 energy sensing to growth control in Wilms tumor cells?
- ? How do induced pluripotent stem cells best model nephrogenesis for renal cancer drug screening?
Recent Trends
The field holds steady at 53,601 works with no 5-year growth data reported.
Highly cited papers from 2006-2007, such as Motzer et al. (5706 citations) and Escudier et al. (4747 citations), continue to define renal-cell carcinoma therapy standards.
No recent preprints or news coverage in the last 12 months.
Research Renal and related cancers with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Renal and related cancers with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers